Evidence map›Paper›PMID 38047923›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2024

DSPE-PEG

Fengyue Yin, Xiao Xu, Julia Qi, Mengyu Guo, Yubo Wang, Yun Wang, Roumei Ye, Qian Lin, Daowei Yang, Xuan Zhu and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Fengyue Yin *Department of Emergency, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, 361005, China.
Xiao Xu *Department of Pharmacy, Medical College of Guangxi University, Nanning, 530004, Guangxi, China.
Julia QiPeking University Health Science Center, Beijing, 100191, China.
Mengyu GuoDepartment of Emergency, Zhongshan Hospital of Xiamen University, Xiamen, 361005, Fujian, China.
Yubo WangDepartment of Biomedical Engineering, Medical College of Guangxi University, Nanning, 530004, Guangxi, China.
Yun WangDepartment of Internal Medicine, School of Clinical Medicine, Jiamusi University, Heilongjiang 154007, Jiamusi, China.
Roumei YeDepartment of Pharmacy, Medical College of Guangxi University, Nanning, 530004, Guangxi, China.
Qian LinFujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen, 361005, Fujian, China.
Daowei YangDepartment of Clinical Sciences, Lund University, 21428, Malmö, Sweden. dwyang@outlook.com.
Xuan ZhuFujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen, 361005, Fujian, China. zhuxuan@xmu.edu.cn.
Jinling WangDepartment of Emergency, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, 361005, China. wjl09202022@163.com.ORCID 0000-0002-9025-9168
Guangxi University · CNXiamen University · CNMalmö University · SEPeking University · CNZhongshan Hospital of Xiamen University · CN

Funding

Natural Science Foundation of Xiamen City 3502720224ZD1222
6 · The paper itself

Abstract

Cancer is a life-threatening disease worldwide. Nanomedicine and nanodelivery systems are recently developed scientific field that employs specific materials in the nanoscale range to deliver drugs. Lipid-based nanoparticles are an ideal delivery system since they exhibit many advantages, including high bioavailability, self-assembly, formulation simplicity, and the ability to exhibit a plethora of physicochemical properties. Herein, we report that phenobarbital sodium can kill cancer cells by using the DSPE-PEG

Indexed as

NanoparticlesNeoplasmsPhosphatidylethanolaminesPolyethylene GlycolsAnimalsDrug Delivery SystemsMethotrexatePyroptosis1,2-distearoylphosphatidylethanolamine1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)MethotrexatePhosphatidylethanolaminesPolyethylene GlycolsFolate receptorsPhenobarbital sodiumPyroptosis

Identifiers

PMID38047923
OpenAlexW4389305585

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.